Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,407
Out of 4,761 analysts
12
Total ratings
n/a
Success rate
-25.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $37.46 | +46.82% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.97 | +169.36% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $12.35 | +183.40% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $9.19 | +95.87% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.42 | +104.68% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $9.28 | -35.34% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.21 | +143.07% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $216 | $4.97 | +4,246.08% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $63.54 | -65.38% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $18.57 | +29.24% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $10.68 | -6.37% | 1 | Oct 26, 2021 |
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $37.46
Upside: +46.82%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.97
Upside: +169.36%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $12.35
Upside: +183.40%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $9.19
Upside: +95.87%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.42
Upside: +104.68%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $9.28
Upside: -35.34%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.21
Upside: +143.07%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $216
Current: $4.97
Upside: +4,246.08%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $63.54
Upside: -65.38%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $18.57
Upside: +29.24%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $10.68
Upside: -6.37%